Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harvard Bioscience (HBIO) Total Liabilities (2016 - 2025)

Harvard Bioscience (HBIO) has disclosed Total Liabilities for 16 consecutive years, with $63.9 million as the latest value for Q3 2025.

  • On a quarterly basis, Total Liabilities fell 3.02% to $63.9 million in Q3 2025 year-over-year; TTM through Sep 2025 was $63.9 million, a 3.02% decrease, with the full-year FY2024 number at $63.3 million, down 1.54% from a year prior.
  • Total Liabilities was $63.9 million for Q3 2025 at Harvard Bioscience, down from $64.4 million in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $81.7 million in Q1 2022 to a low of $61.7 million in Q2 2024.
  • A 5-year average of $70.0 million and a median of $67.5 million in 2023 define the central range for Total Liabilities.
  • Peak YoY movement for Total Liabilities: grew 10.16% in 2022, then dropped 13.19% in 2023.
  • Harvard Bioscience's Total Liabilities stood at $78.9 million in 2021, then decreased by 7.35% to $73.1 million in 2022, then dropped by 12.1% to $64.3 million in 2023, then dropped by 1.54% to $63.3 million in 2024, then grew by 0.98% to $63.9 million in 2025.
  • Per Business Quant, the three most recent readings for HBIO's Total Liabilities are $63.9 million (Q3 2025), $64.4 million (Q2 2025), and $65.0 million (Q1 2025).